Liver Cancer Therapy

Copper chelator trientine mediates liver cancer killing

Published in Hepatitis Weekly, December 9th, 2002

by Sonia Nichols, senior medical writer - Agents that capture copper could be effective therapy for hepatocellular carcinoma.

Researchers believe the pathogenesis of hepatocellular carcinoma, linked to viral hepatitis, cirrhosis, and exposure to liver toxins, is innately proangiogenic. Thus, scientists have begun to explore drugs that can block angiogenesis in hepatocellular carcinomas. There is at least one agent, a copper chelator known as trientine, that has demonstrated antiangiogenic effects in murine models of liver cancer.

According to Michihisa Moriguchi and coauthors at Kyoto Prefectural University of Medicine in Kyoto, Japan, trientine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry